TESTODERM TTS Drug Patent Profile
✉ Email this page to a colleague
When do Testoderm Tts patents expire, and when can generic versions of Testoderm Tts launch?
Testoderm Tts is a drug marketed by Alza and is included in one NDA.
The generic ingredient in TESTODERM TTS is testosterone. There are sixty-nine drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the testosterone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Testoderm Tts
A generic version of TESTODERM TTS was approved as testosterone by ACTAVIS LABS UT INC on January 27th, 2006.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TESTODERM TTS?
- What are the global sales for TESTODERM TTS?
- What is Average Wholesale Price for TESTODERM TTS?
Summary for TESTODERM TTS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 73 |
| Patent Applications: | 4,287 |
| DailyMed Link: | TESTODERM TTS at DailyMed |
US Patents and Regulatory Information for TESTODERM TTS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alza | TESTODERM TTS | testosterone | FILM, EXTENDED RELEASE;TRANSDERMAL | 020791-001 | Dec 18, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TESTODERM TTS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Alza | TESTODERM TTS | testosterone | FILM, EXTENDED RELEASE;TRANSDERMAL | 020791-001 | Dec 18, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Alza | TESTODERM TTS | testosterone | FILM, EXTENDED RELEASE;TRANSDERMAL | 020791-001 | Dec 18, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for TESTODERM TTS
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Warner Chilcott UK Ltd. | Intrinsa | testosterone | EMEA/H/C/000634 Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy. |
Withdrawn | no | no | no | 2006-07-28 | |
| Warner Chilcott Deutschland GmbH | Livensa | testosterone | EMEA/H/C/000630 Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy. |
Withdrawn | no | no | no | 2006-07-28 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for TESTODERM TTS
See the table below for patents covering TESTODERM TTS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| France | 2499859 | DISPOSITIF D'ADMINISTRATION SIMULTANEE D'UNE SUBSTANCE PHARMACEUTIQUE ET D'UN ACTIVATEUR D'ABSORPTION PERCUTANEE | ⤷ Sign Up |
| Singapore | 68387 | ⤷ Sign Up | |
| Ireland | 820296 | ⤷ Sign Up | |
| Italy | 1218310 | UNITA DI DOSAGGIO PER LA SOMMINISTRAZIONE CONTEMPORANEA DI UN MEDICAMNETO E DI INTENSIFICATORE DI ASSORBIMENTO PERCUTANEO | ⤷ Sign Up |
| Australia | 7954582 | ⤷ Sign Up | |
| Ireland | 52930 | DOSAGE FORM FOR COADMINISTERING DRUG AND PERCUTANEOUS ABSORPTION ENHANCER | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
